ReviewMolecular neurobiology2020
Current and Future Therapies for Psoriasis with a Focus on Serotonergic Drugs.
Review in Molecular neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Cherry plum powder alleviates excessive proliferation and inflammation of keratinocytes in psoriasis by reducing N6 methyladenosine-modified S100A4.Journal of molecular histology · 2026Article
- Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives.Recent advances in inflammation & allergy drug discovery · 2025Review
- Antipsoriatic Effect of Silymarin NLCs Based Gel: In Vitro and In Vivo Activity.AAPS PharmSciTech · 2024Article
- Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.PloS one · 2024Article
- She-Chuang-Si-Wu-Tang Alleviates Inflammation and Itching Symptoms in a Psoriasis Mouse Model by Regulating the Th17/IL-17 Axis via the STAT3/MAPK Pathways.Journal of inflammation research · 2024Article
- Multi-target mechanism ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Pathology and Treatment of Psoriasis Using Nanoformulations.Biomedicines · 2023Review
- Can Essential Oils/Botanical Agents Smart-Nanoformulations Be the Winning Cards against Psoriasis?Pharmaceutics · 2023Review
- Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease.Frontiers in immunology · 2023Review
- Nanoscale Topical Pharmacotherapy in Management of Psoriasis: Contemporary Research and Scope.Journal of functional biomaterials · 2022Review
- Treatments in psoriasis: from standard pharmacotherapy to nanotechnology therapy.Postepy dermatologii i alergologii · 2022Review
- Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Th17-cells in depression: Implication in multiple sclerosis.Frontiers in immunology · 2022Review
- Novel Therapeutic Target(s) for Psoriatic Disease.Frontiers in medicine · 2022Review
- Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects.RSC advances · 2021Review
- Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis.AAPS PharmSciTech · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Psoriasis is a chronic immune-mediated skin disease, with a pathogenesis resulting from a combination of genetic and environmental factors. The pathogenesis of psoriasis is driven by the interaction between innate and adaptive immune cells and keratinocytes, in a complex process mediated by cytokines and other signaling molecules. This leads to an inflammatory process with increased proliferation of epidermal cells, neo-angiogenesis, and infiltration of white cells in the skin, which cause the characteristic psoriasis plaques. Several studies have suggested that the neurotransmitter serotonin, a key mediator between the skin and the neuroendocrine system, also plays an important role in the pathogenesis of psoriasis. Psoriasis often needs long-term treatment, which can be a burden. Thus, the choice of the treatment is crucial to increase the patients' adherence and quality of life. This review addresses the currently available systemic and topical treatments for psoriasis, used by themselves or combined with phototherapy. It particularly focuses on the importance of advanced drug delivery systems as a way to increase the drug penetration and retention in the skin, while also enhancing its solubility and stability. Finally, we discuss the role of the serotonin system in psoriasis, and summarize what is known about the effects of antidepressants, in particular specific serotonin reuptake inhibitors, on the physical symptoms of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.